Feinstein Institutes' Bioelectronic Medicine Summit Highlights Breakthroughs in Neuromodulation and Brain-Computer Interfaces

  • The Feinstein Institutes for Medical Research hosted its seventh annual Bioelectronic Medicine Summit on September 28-29, 2026, in New York City.
  • Nearly 300 experts from leading institutions worldwide attended the sold-out event, which featured keynote addresses from MIT’s Edward S. Boyden and Caltech’s Mikhail G. Shapiro.
  • Three Northwell clinical trial participants were recognized for their contributions to advancing neurotechnologies, including a double neural bypass system and brain-computer interface technology.
  • The summit highlighted advancements in device-based therapies from more than 15 companies, focusing on areas such as cardiac care, respiratory treatment, and neuromodulation to treat cancer.
  • The Feinstein Institutes emphasized its role as the global scientific home of bioelectronic medicine, combining molecular medicine, neuroscience, and biomedical engineering to develop new device-based therapies.

The Feinstein Institutes' Bioelectronic Medicine Summit underscores the growing convergence of molecular medicine, neuroscience, and biomedical engineering, driving the development of innovative device-based therapies. This event highlights the strategic shift towards neuromodulation and brain-computer interfaces as key areas of focus in the healthcare industry, with potential applications across a wide range of diseases and conditions. The summit also emphasizes the importance of global scientific cooperation in advancing these technologies, which could revolutionize the treatment of diseases such as arthritis, pulmonary hypertension, Crohn’s disease, and cancer.

Clinical Validation
How the success of clinical trial participants will influence the adoption of bioelectronic medicine therapies.
Industry Collaboration
The pace at which partnerships between academic institutions and industry players will accelerate advancements in bioelectronic medicine.
Regulatory Approvals
Whether the growing body of research will lead to faster regulatory approvals for bioelectronic medicine devices.